SG10201912192RA - IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS - Google Patents
IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORSInfo
- Publication number
- SG10201912192RA SG10201912192RA SG10201912192RA SG10201912192RA SG10201912192RA SG 10201912192R A SG10201912192R A SG 10201912192RA SG 10201912192R A SG10201912192R A SG 10201912192RA SG 10201912192R A SG10201912192R A SG 10201912192RA SG 10201912192R A SG10201912192R A SG 10201912192RA
- Authority
- SG
- Singapore
- Prior art keywords
- imidazo
- pyrazine derivatives
- pi3kdelta
- inhibitors
- pi3kdelta inhibitors
- Prior art date
Links
- 102100036056 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Human genes 0.000 title 1
- 101710204747 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Proteins 0.000 title 1
- MIFJMFOVENWQDP-UHFFFAOYSA-N imidazo[1,5-a]pyrazine Chemical class C1=CN=CC2=CN=CN21 MIFJMFOVENWQDP-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016108897 | 2016-12-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201912192RA true SG10201912192RA (en) | 2020-02-27 |
Family
ID=62491736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912192RA SG10201912192RA (en) | 2016-12-07 | 2017-12-07 | IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11136323B2 (enExample) |
| EP (1) | EP3551630A4 (enExample) |
| JP (2) | JP7064495B2 (enExample) |
| KR (1) | KR20190091339A (enExample) |
| CN (2) | CN114805366A (enExample) |
| AU (2) | AU2017372377B2 (enExample) |
| BR (1) | BR112019011847A2 (enExample) |
| CA (1) | CA3045959A1 (enExample) |
| EA (1) | EA201991355A1 (enExample) |
| IL (2) | IL266986B (enExample) |
| MX (1) | MX394882B (enExample) |
| NZ (1) | NZ754944A (enExample) |
| SG (1) | SG10201912192RA (enExample) |
| TW (2) | TWI762534B (enExample) |
| WO (1) | WO2018103688A1 (enExample) |
| ZA (1) | ZA201903286B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3551630A4 (en) | 2016-12-07 | 2020-07-15 | Beigene, Ltd. | IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3KDELTA INHIBITORS |
| IL272988B (en) | 2017-09-08 | 2022-08-01 | Beigene Ltd | Imidazo-[1,5-a]pyrazine derivatives as pi3k-delta inhibitors |
| US20230011916A1 (en) * | 2019-11-21 | 2023-01-12 | Beigene, Ltd. | Methods of cancer treatment using anti-ox40 antibodies in combination with pi3 kinase delta inhibitors |
| KR102344185B1 (ko) * | 2020-02-26 | 2021-12-27 | 계명대학교 산학협력단 | 신규한 Pim 키나아제 억제제 및 이의 용도 |
| IL308856A (en) * | 2021-05-27 | 2024-01-01 | Beigene Switzerland Gmbh | SALTS OF A PI3Kdelta INHIBITOR, CRYSTALLINE FORMS, METHODS OF PREPARATION, AND USES THEREFORE |
| JP2024535799A (ja) * | 2021-09-14 | 2024-10-02 | ベイジーン スウィッツァーランド ゲーエムベーハー | Ｂｔｋ阻害剤及びｐｉ３キナーゼ阻害剤の組み合わせを使用したがん治療の方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2372694T3 (es) | 2003-10-15 | 2012-01-25 | OSI Pharmaceuticals, LLC | Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina. |
| NZ596185A (en) | 2009-04-16 | 2013-01-25 | Ct Nac Investigaciones Oncologicas Cnio | Imidazopyrazines for use as kinase inhibitors |
| RU2013138835A (ru) | 2011-02-09 | 2015-03-20 | Ф. Хоффманн-Ля Рош Аг | Гетероциклические соединения в качестве ингибиторов pi3 киназы |
| WO2013104610A1 (en) * | 2012-01-10 | 2013-07-18 | Bayer Intellectual Property Gmbh | Substituted imidazopyrazines as akt kinase inhibitors |
| KR102229478B1 (ko) | 2012-11-01 | 2021-03-18 | 인피니티 파마슈티칼스, 인코포레이티드 | Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료 |
| ES2834638T3 (es) * | 2013-05-30 | 2021-06-18 | Infinity Pharmaceuticals Inc | Tratamiento de cánceres usando moduladores de isoforma de PI3 cinasa |
| CA2922058A1 (en) * | 2013-10-18 | 2015-04-23 | Medivation Technologies, Inc. | Heterocyclic compounds and methods of use |
| RS62713B1 (sr) | 2014-08-11 | 2022-01-31 | Acerta Pharma Bv | Terapeutske kombinacije btk inhibitora i bcl-2 inhibitora |
| EP3551630A4 (en) * | 2016-12-07 | 2020-07-15 | Beigene, Ltd. | IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3KDELTA INHIBITORS |
| IL272988B (en) | 2017-09-08 | 2022-08-01 | Beigene Ltd | Imidazo-[1,5-a]pyrazine derivatives as pi3k-delta inhibitors |
-
2017
- 2017-12-07 EP EP17877406.3A patent/EP3551630A4/en not_active Withdrawn
- 2017-12-07 US US16/466,621 patent/US11136323B2/en active Active
- 2017-12-07 TW TW106143023A patent/TWI762534B/zh not_active IP Right Cessation
- 2017-12-07 EA EA201991355A patent/EA201991355A1/ru unknown
- 2017-12-07 TW TW111114434A patent/TW202233190A/zh unknown
- 2017-12-07 CA CA3045959A patent/CA3045959A1/en active Pending
- 2017-12-07 BR BR112019011847-0A patent/BR112019011847A2/pt not_active IP Right Cessation
- 2017-12-07 NZ NZ754944A patent/NZ754944A/en not_active IP Right Cessation
- 2017-12-07 CN CN202210507333.8A patent/CN114805366A/zh active Pending
- 2017-12-07 WO PCT/CN2017/114970 patent/WO2018103688A1/en not_active Ceased
- 2017-12-07 SG SG10201912192RA patent/SG10201912192RA/en unknown
- 2017-12-07 AU AU2017372377A patent/AU2017372377B2/en not_active Ceased
- 2017-12-07 MX MX2019006612A patent/MX394882B/es unknown
- 2017-12-07 CN CN201780076039.3A patent/CN110267959B/zh not_active Expired - Fee Related
- 2017-12-07 JP JP2019530790A patent/JP7064495B2/ja not_active Expired - Fee Related
- 2017-12-07 KR KR1020197019710A patent/KR20190091339A/ko not_active Ceased
-
2019
- 2019-05-24 ZA ZA2019/03286A patent/ZA201903286B/en unknown
- 2019-05-29 IL IL266986A patent/IL266986B/en unknown
-
2021
- 2021-07-08 US US17/370,728 patent/US11725012B2/en active Active
-
2022
- 2022-02-07 IL IL290419A patent/IL290419B2/en unknown
- 2022-04-22 JP JP2022070763A patent/JP2022090051A/ja active Pending
- 2022-05-31 AU AU2022203737A patent/AU2022203737A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW202233190A (zh) | 2022-09-01 |
| EP3551630A1 (en) | 2019-10-16 |
| US20190367523A1 (en) | 2019-12-05 |
| US11136323B2 (en) | 2021-10-05 |
| JP7064495B2 (ja) | 2022-05-10 |
| AU2017372377B2 (en) | 2022-03-03 |
| IL266986B (en) | 2022-03-01 |
| IL290419A (en) | 2022-04-01 |
| US11725012B2 (en) | 2023-08-15 |
| AU2017372377A1 (en) | 2019-07-18 |
| TW201833113A (zh) | 2018-09-16 |
| JP2022090051A (ja) | 2022-06-16 |
| EP3551630A4 (en) | 2020-07-15 |
| MX2019006612A (es) | 2019-08-01 |
| IL290419B2 (en) | 2023-02-01 |
| CA3045959A1 (en) | 2018-06-14 |
| CN114805366A (zh) | 2022-07-29 |
| NZ754944A (en) | 2023-02-24 |
| MX394882B (es) | 2025-03-24 |
| WO2018103688A1 (en) | 2018-06-14 |
| TWI762534B (zh) | 2022-05-01 |
| AU2022203737A1 (en) | 2022-06-23 |
| CN110267959A (zh) | 2019-09-20 |
| CN110267959B (zh) | 2022-05-27 |
| ZA201903286B (en) | 2021-01-27 |
| KR20190091339A (ko) | 2019-08-05 |
| IL266986A (en) | 2019-07-31 |
| US20220098202A1 (en) | 2022-03-31 |
| JP2020500909A (ja) | 2020-01-16 |
| IL290419B (en) | 2022-10-01 |
| EA201991355A1 (ru) | 2019-11-29 |
| BR112019011847A2 (pt) | 2019-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277576A (en) | Mutated pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | |
| IL260923B (en) | History of pyrazolo[5,1-a]pyrazin-4-yl as jak inhibitors | |
| IL265918B (en) | Converted pyrazolo[1,5–a]pyridine compounds as ret kinase inhibitors | |
| ZA201800771B (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| IL266305B (en) | History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors | |
| IL254224A0 (en) | 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors | |
| ZA201704494B (en) | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors | |
| ZA201802842B (en) | [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound | |
| IL290419B (en) | Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta | |
| IL247947B (en) | 7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrazine compounds and 8,7,6,5-tetrahydro-h4-pyrazolo[5,1-a][4,1]diazepine compounds as ros1 inhibitors | |
| IL272988A (en) | Imidazo-[1,5-A]pyrazine derivatives as PI3K-delta inhibitors | |
| IL247948B (en) | 7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrimidine derivatives and 3,2-dihydro-h1-imidazo[2,1-b]pyrazole derivatives as ros1 inhibitors | |
| IL262673A (en) | A pyrazolo[5,1-a]pyrimidine compound | |
| ZA201608079B (en) | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | |
| HK1238236A1 (en) | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors |